Greg Yothers

Greg Yothers

UNVERIFIED PROFILE

Are you Greg Yothers?   Register this Author

Register author
Greg Yothers

Greg Yothers

Publications by authors named "Greg Yothers"

Are you Greg Yothers?   Register this Author

71Publications

2091Reads

48Profile Views

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer.

Clin Gastroenterol Hepatol 2019 Dec 4. Epub 2019 Dec 4.

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA; Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2019.11.046DOI Listing
December 2019

Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).

Br J Cancer 2018 03 14;118(5):629-633. Epub 2017 Dec 14.

National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846062PMC
March 2018

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

J Clin Oncol 2017 Aug 11;35(23):2647-2655. Epub 2017 Apr 11.

Joanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.4147
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.4147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549453PMC
August 2017

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.

JAMA Oncol 2016 Sep;2(9):1162-9

National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology, Pittsburgh, Pennsylvania7Division of Medical Oncology, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065181PMC
http://dx.doi.org/10.1001/jamaoncol.2016.2314DOI Listing
September 2016

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

J Clin Oncol 2016 Apr 8;34(11):1182-9. Epub 2016 Feb 8.

Winson Y. Cheung, British Columbia Cancer Agency, Vancouver, British Columbia; Chris O'Callaghan, Queen's University, Kingston, Ontario, Canada; Lindsay A. Renfro, Axel Grothey, Steven R. Alberts, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; David Kerr, University of Oxford, Oxford; Chris Twelves, University of Leeds and St James Institute of Oncology, Leeds, United Kingdom; Aimery de Gramont, Franco-British Institute, Levallois-Perret; Thierry Andre, Hospital Saint-Antoine and Pierre and Marie Curie University, Paris; Jean-Francois Seitz, La Timone Hospital, Aix-Marseille University, Marseille, France; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Katherine A. Guthrie, Fred Hutchinson Cancer Center, Seattle, WA; Roberto Labianca, Ospedale Giovanni XXIII, Bergamo; Guido Francini, University of Siena, Siena, Italy; Eric Van Cutsem, University Hospital Leuven, Leuven, Belgium; Daniel G. Haller, University of Pennsylvania, Philadelphia; and Greg Yothers, University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.1158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933130PMC
April 2016

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

J Clin Oncol 2016 Mar 25;34(8):843-53. Epub 2016 Jan 25.

Manish A. Shah, Weill Cornell Medical College, New York/Presbyterian Hospital, New York, NY; Lindsay A. Renfro, Steven R. Alberts, and Daniel J. Sargent, Mayo Clinic, Rochester, MN; Carmen J. Allegra, University of Florida, Gainesville, FL; Thierry André, Hôpital Saint Antoine, Paris; Aimery de Gramont, Franco-British Institute, Levallois-Perret, France; Hans-Joachim Schmoll, University Clinic Halle (Saale), Halle, Germany; Daniel G. Haller, University of Pennsylvania, Philadelphia; and Greg Yothers, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/21/JCO.2015.63
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.0558
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.0558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872008PMC
March 2016

Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer.

JAMA Oncol 2016 Jan;2(1):23-4

NRG Oncology, Pittsburgh, Pennsylvania3Division of Hematology & Oncology, University of Florida, Gainesville.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.3614DOI Listing
January 2016

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

N Engl J Med 2016 Jan;374(3):211-22

From the Herbert Irving Comprehensive Cancer Center and the Departments of Pathology and Cell Biology and Medicine, Columbia University, New York (P.D.); Institute for Stem Cell Biology and Regenerative Medicine (P.D., D.S., P.S.R., S.P.M., S.H., J.H., D.Q., M.F.C.) and the Departments of Pathology (X.G., E.F., M.R.), and Medicine, Division of Oncology (N.W.-F., G.A.F., M.F.C.), Stanford University, Stanford, and the Departments of Pediatrics and Computer Science and Engineering, University of California San Diego, San Diego (D.S.) - both in California; Faculty of Engineering, Bar-Ilan University, Ramat Gan, Israel (T.K.); the National Surgical Adjuvant Breast and Bowel Project, NRG Oncology (S.P., G.Y., N.S., N.W.) and the Allegheny Cancer Center at Allegheny General Hospital (N.W.) - both in Pittsburgh; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea (S.P.); and the Department of Biochemistry and Molecular Biology, Medical School of Henan University, Kaifeng, China (X.G.).

View Article

Download full-text PDF

Source
http://news.medlive.cn/uploadfile/20160121/14533511633728.pd
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1506597
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1506597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784450PMC
January 2016

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

J Natl Cancer Inst 2015 Nov 14;107(11). Epub 2015 Sep 14.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA (CJA, GY, MJO, RWB, TFW, HCP, AFS, JCL, DPR, AA, LSE, NB, GS, JFE, JMR, DFMJr, MRM, BTM, PJW, SS, MSR, NW); Department of Medicine, University of Florida Health, Gainesville, FL (CJA); NRG Oncology and the University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA (GY); Glendale Memorial Hospital, Glendale, CA (RWB); CCOP Christiana Care Health Systems, Newark, DE (TFW); Mayo Clinic, Rochester, MN and the ALLIANCE, Boston, MA (HCP); Wayne State University, Karmanos Cancer Institute, Detroit, MI and SWOG, San Antonio, TX (AFS); Emory University, Department of Radiation Oncology, Atlanta, GA and ECOG/ACRIN, Rochester, MN (JCL); Massachusetts General Hospital Cancer Center and the ALLIANCE, Boston, MA (DPR); Kaiser Permanente, Fremont, CA (AA); Novant Health Forsyth Medical Center, Winston-Salem, NC (LSE); University of Pittsburgh, Pittsburgh, PA (NB); Missouri Valley Cancer Consortium CCOP, Omaha, NE (GS); Florida Cancer Specialists, Fort Myers, FL (JFE); Beaumont Hospital System, Royal Oak, MI (JMR); Cancer Center of Kansas, Wichita, KS (DFMJr); Stroger Hospital Chicago MU-NCORP, Chicago, IL (MRM); Montana Cancer Consortium, Billings, MT (BTM); Oncology and Hematology Care, Cincinnati, OH (PJW); UF Health Cancer Center, Orlando FL (MSR); Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (NW).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849360PMC
November 2015

Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04.

Ann Surg 2015 Jan;261(1):144-8

*National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh, PA †David Geffen School of Medicine at UCLA, VA Greater Los Angeles Healthcare System, Los Angeles, CA ‡UCLA Schools of Medicine & Public Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA §University of Pittsburgh Graduate School of Public Health Department of Biostatistics, Pittsburgh, PA ∥UCLA, Los Angeles, CA ¶Kaiser Permanente Oncology Clinical Trials, Northern California, Vallejo, CA **Southeast Cancer Control Consortium CCOP, Goldsboro, NC ††University of Pittsburgh Medical Center, Pittsburgh, PA ‡‡Missouri Valley Cancer Consortium CCOP, Omaha, NE §§Beaumont Hospital System, Royal Oak, MI ∥∥Florida Cancer Specialists, Sarasota, FL ¶¶Montana Cancer Consortium, Billings, MT ***Helen F. Graham Cancer Center, Newark, DE †††Glendale Memorial Hospital and Health Center, Glendale, CA ‡‡‡Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/annalsofsurgery/2015/01000/Comp
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/SLA.0000000000000594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379325PMC
January 2015

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Curr Colorectal Cancer Rep 2015;11(5):275-280

University of Pittsburgh, One Sterling Plaza, 201 N Craig St, Ste 350, Pittsburgh, PA 15213 USA ; NRG Oncology, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11888-015-0285-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550644PMC
January 2015

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

J Natl Cancer Inst 2014 Dec 29;106(12). Epub 2014 Oct 29.

Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN (LAR, DJS); Department of Oncology, Mayo Clinic, Rochester, MN (AMG, SRA, CLL); Department of Statistics, University of Virginia, Charlottesville, VA (YX); Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY (LBS); Hôpital Saint Antoine, Paris, France; Pierre and Marie Curie University, Paris, France (TA); Leeds Institute of Cancer and Pathology, University of Leeds and St. James's University Hospital, Leeds Cancer Research UK Centre, UK (CT); Oncology Unit, Ospedale Giovanni XXIII, Bergamo, Italy (RL); Division of Hematology and Oncology, University of Florida, Gainesville, FL (CJA); National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA (GY).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/106/12/dju333.full.pd
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/dju333
Publisher Site
http://dx.doi.org/10.1093/jnci/dju333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334801PMC
December 2014

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

J Clin Oncol 2014 Jun 5;32(18):1927-34. Epub 2014 May 5.

Michael J. O'Connell, Linda H. Colangelo, Robert W. Beart, Nicholas J. Petrelli, Carmen J. Allegra, Saima Sharif, Henry C. Pitot, Anthony F. Shields, David S. Parda, Mohammed Mohiuddin, Amit Arora, Lisa S. Evans, Nathan Bahary, Gamini S. Soori, Janice Eakle, John M. Robertson, Dennis F. Moore Jr, Michael R. Mullane, Benjamin T. Marchello, Patrick J. Ward, Timothy F. Wozniak, Mark S. Roh, Greg Yothers, Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers; David S. Parda, Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital; Nathan Bahary, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA; Robert W. Beart, Colorectal Surgery Institute, Glendale Memorial Hospital, Glendale; Amit Arora, Kaiser Permanente Hayward, Hayward, CA; Nicholas J. Petrelli, Timothy F. Wozniak, Helen F. Graham Cancer Center at Christiana Care Health Service, Newark, DE; Carmen J. Allegra, University of Florida, Gainesville; Janice Eakle, Florida Cancer Specialists, Sarasota; Mark S. Roh, MD Anderson Cancer Center Orlando Health, Orlando, FL; Henry C. Pitot, Mayo Clinic, Rochester, MN; Anthony F. Shields, Karmanos Cancer Institute/Southwest Oncology Group, Detroit; John M. Robertson, Beaumont Hospital System, Royal Oak, MI; Jerome C. Landry, Eastern Cooperative Oncology Group/Emory University, Winship Cancer Institute, Atlanta, GA; David P. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA; Lisa S. Evans, Community Clinical Oncology Program, Southeast CCC Novant Health Derrick L. Davis Forsyth Medical Center, Winston-Salem, NC; Gamini S. Soori, Missouri Valley Cancer Consortium Community Clinical Oncology Program, Omaha, NE; Dennis Moore Jr, Community Clinical Oncology Program, Wichita/St Francis Regional Medical Center/Via Christi Regional Medical Center, Wichita, KS; Michael R. Mullane, Minority-Based Community Clinical Oncology Program John H. Stroger Jr Hospital

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.53.7753
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.53.7753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050205PMC
June 2014

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

J Clin Oncol 2013 Dec 12;31(36):4512-9. Epub 2013 Nov 12.

Greg Yothers, Michael J. O'Connell, Soonmyung Paik, Saima Sharif, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers; Greg Yothers, University of Pittsburgh Graduate School of Public Health; Saima Sharif and Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA; Mark Lee, Margarita Lopatin, Kim M. Clark-Langone, and Steven Shak, Genomic Health, Redwood City, CA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/11/04/JCO.2012.47
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.47.3116
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.3116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871512PMC
December 2013

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.

J Clin Oncol 2013 Oct 26;31(29):3656-63. Epub 2013 Aug 26.

Qian Shi, Axel Grothey, Brian M. Bot, and Daniel J. Sargent, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN; Thierry Andre, Hôpital Saint Antoine, Paris, France; Greg Yothers and Michael J. O'Connell, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh; Daniel G. Haller, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Stanley R. Hamilton, University of Texas MD Anderson Cancer Center, Houston, TX; Brian M. Bot, Sage Bionetworks; Jacqueline K. Benedetti, Southwest Oncology Group Statistical Center, Seattle, WA; Eric Van Cutsem, University Hospital Gasthuisberg, Gasthuisberg, Belgium; and Chris Twelves, St James's University Hospital, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.4344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804289PMC
October 2013

Colon cancer mutation: prognosis/prediction--response.

Clin Cancer Res 2013 Mar 8;19(5):1301. Epub 2013 Feb 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0020DOI Listing
March 2013

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

J Clin Oncol 2013 Jan 10;31(3):359-64. Epub 2012 Dec 10.

University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N-503, Gainesville, FL 32610, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.4711DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732014PMC
January 2013

A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.

Clin Trials 2012 Aug 18;9(4):385-95. Epub 2012 Jul 18.

Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774512450101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598604PMC
August 2012

Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.

Clin Trials 2011 Oct 15;8(5):581-90. Epub 2011 Sep 15.

Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774511414741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3197975PMC
October 2011

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

J Natl Cancer Inst 2011 Oct 12;103(20):1498-506. Epub 2011 Oct 12.

National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, One Sterling Plaza, 201 N Craig St, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196480PMC
October 2011

Simultaneous Confidence Band for the Difference of Segmented Linear Models.

J Stat Plan Inference 2011 Feb;141(2):1059-1068

Department of Statistics, University of Pittsburgh, Pittsburgh Pennsylvania 15260, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jspi.2010.09.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498589PMC
February 2011

Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.

J Natl Cancer Inst 2011 Jan 1;103(1):4-5. Epub 2010 Dec 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq483DOI Listing
January 2011

Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

J Clin Oncol 2009 Nov 21;27(31):5124-30. Epub 2009 Sep 21.

National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations Cente, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.0467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773471PMC
November 2009

Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group.

J Cancer Surviv 2009 Sep 13;3(3):137-47. Epub 2009 Jun 13.

School of Public Health & David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11764-009-0093-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714451PMC
September 2009

NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).

NIH Consens State Sci Statements 2009 Sep;26(2):1-27

University of Florida Shands Cancer Center, University of Florida, Gainesville, Florida, USA.

View Article

Download full-text PDF

Source
September 2009

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.

Cancer Invest 2008 Nov;26(9):956-63

National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900802132550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588473PMC
November 2008

Exploring and validating surrogate endpoints in colorectal cancer.

Lifetime Data Anal 2008 Mar 20;14(1):54-64. Epub 2008 Jan 20.

Center for Statistics, Hasselt University, Agoralaan D, 3590 Diepenbeek, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10985-007-9079-4DOI Listing
March 2008

Toward progression-free survival as a primary end point in advanced colorectal cancer.

Authors:
Greg Yothers

J Clin Oncol 2007 Nov;25(33):5153-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.6796DOI Listing
November 2007

Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

J Natl Cancer Inst 2006 Nov;98(22):1647-54

Department of Health Studies, 5841 South Maryland Ave., MC 2007, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/98/22/1647.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djj442
Publisher Site
http://dx.doi.org/10.1093/jnci/djj442DOI Listing
November 2006

Randomization in Phase II Clinical Trials.

Clin Adv Hematol Oncol 2006 Oct;4(10):776-8

NSABP Biostatistical Center, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
October 2006

Prevalence of burnout in the u.s. Oncology community: results of a 2003 survey.

J Oncol Pract 2005 Nov;1(4):140-7

Network for Medical Communication and Research, Atlanta GA, and Biostatistical Program, University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794568PMC
http://dx.doi.org/10.1200/JOP.2005.1.4.140DOI Listing
November 2005

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

J Clin Oncol 2005 Jun 16;23(16):3686-96. Epub 2005 May 16.

National Surgical Adjuvant Breast and Bowel Project, Operations Office and Biostatistical Center, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.10.517DOI Listing
June 2005

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

J Natl Cancer Inst 2002 Jun;94(11):852-4

National Surgical Adjuvant Breast and Bowel Project (NSABP) Operation Center, Pittsburgh, PA 15212, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/94.11.852DOI Listing
June 2002